

Joseph A Lasky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6676131/publications.pdf>

Version: 2024-02-01

55
papers

8,660
citations

236833

25
h-index

161767

54
g-index

59
all docs

59
docs citations

59
times ranked

9184
citing authors

#	ARTICLE	IF	CITATIONS
1	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	2.5	6,033
2	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 948-955.	2.5	338
3	Abrogation of TGF- β 1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L864-L870.	1.3	193
4	Expression of TNF and the Necessity of TNF Receptors in Bleomycin-Induced Lung Injury in Mice. Experimental Lung Research, 1998, 24, 721-743.	0.5	166
5	Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 275, L365-L371.	1.3	146
6	Requirement of HDAC6 for Transforming Growth Factor- β 1-induced Epithelial-Mesenchymal Transition. Journal of Biological Chemistry, 2008, 283, 21065-21073.	1.6	143
7	Emphysematous Lesions, Inflammation, and Fibrosis in the Lungs of Transgenic Mice Overexpressing Platelet-Derived Growth Factor. American Journal of Pathology, 1999, 154, 1763-1775.	1.9	125
8	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 116.	1.4	114
9	Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1200-1207.	2.5	101
10	Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). Journal of Thoracic Disease, 2019, 11, S1740-S1754.	0.6	89
11	Rapid Activation of PDGF-A and -B Expression at Sites of Lung Injury in Asbestos-exposed Rats. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 129-140.	1.4	86
12	Tubastatin ameliorates pulmonary fibrosis by targeting the TGF β -PI3K-Akt pathway. PLoS ONE, 2017, 12, e0186615.	1.1	76
13	Brainstem Activation of Platelet-Derived Growth Factor- β 2 Receptor Modulates the Late Phase of the Hypoxic Ventilatory Response. Journal of Neurochemistry, 2001, 74, 310-319.	2.1	66
14	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 94-104.	0.4	66
15	Engraftment of Bone Marrow Progenitor Cells in a Rat Model of Asbestos-Induced Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 385-394.	2.5	63
16	Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L182-L188.	1.3	60
17	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine, 2020, 20, 64.	0.8	59
18	The Epstein-Barr Virus Latent Membrane Protein 1 and Transforming Growth Factor- β 1 Synergistically Induce Epithelial to Mesenchymal Transition in Lung Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 852-862.	1.4	56

#	ARTICLE	IF	CITATIONS
19	Antifibrotic Therapy for the Treatment of Pulmonary Fibrosis. American Journal of the Medical Sciences, 2001, 322, 213-221.	0.4	47
20	Arsenic trioxide inhibits transforming growth factor- β 21-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respiratory Research, 2014, 15, 51.	1.4	46
21	HDAC8 inhibition ameliorates pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L175-L186.	1.3	43
22	Requirement of HDAC6 for activation of Notch1 by TGF- β 21. Scientific Reports, 2016, 6, 31086.	1.6	34
23	Regulatory effects of IL-15 on allergen-induced airway obstruction. Journal of Allergy and Clinical Immunology, 2018, 141, 906-917.e6.	1.5	31
24	Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology, 2011, 416, 86-97.	1.1	30
25	Overexpression of Sulf2 in idiopathic pulmonary fibrosis. Glycobiology, 2013, 23, 709-719.	1.3	29
26	A critical role for IL-18 in transformation and maturation of naive eosinophils to pathogenic eosinophils. Journal of Allergy and Clinical Immunology, 2018, 142, 301-305.	1.5	27
27	Detecting Splicing Variants in Idiopathic Pulmonary Fibrosis from Non-Differentially Expressed Genes. PLoS ONE, 2013, 8, e68352.	1.1	26
28	Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology, 2010, 15, 19-31.	1.3	24
29	Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer. Translational Oncology, 2020, 13, 135-145.	1.7	24
30	BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans. Obesity, 2020, 28, 1798-1801.	1.5	24
31	Over-expression of PDGF-C using a lung specific promoter results in abnormal lung development. Transgenic Research, 2006, 15, 543-555.	1.3	22
32	Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. Respiratory Investigation, 2018, 56, 375-383.	0.9	22
33	Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. Advances in Therapy, 2020, 37, 4209-4219.	1.3	21
34	Using Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases. Chest, 2020, 158, 2015-2025.	0.4	21
35	Update in Interstitial Lung Disease 2020. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1343-1352.	2.5	21
36	PDGF- β 2 receptor expression and ventilatory acclimatization to hypoxia in the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R1625-R1633.	0.9	20

#	ARTICLE	IF	CITATIONS
37	Methylation status and AP1 elements are involved in EBV-mediated miR-155 expression in EBV positive lymphoma cells. <i>Virology</i> , 2016, 494, 158-167.	1.1	20
38	TGF- β ¹ stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L936-L944.	1.3	19
39	The Antiretroviral Agent Nelfinavir Mesylate. <i>Arthritis and Rheumatology</i> , 2018, 70, 115-126.	2.9	15
40	Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2019, 26, 245-249.	0.8	13
41	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019, 9, 14802.	1.6	12
42	Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq. <i>BMC Pulmonary Medicine</i> , 2020, 20, 81.	0.8	12
43	Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. <i>Advances in Therapy</i> , 2021, 38, 782-791.	1.3	12
44	Pirfenidone. <i>IDrugs: the Investigational Drugs Journal</i> , 2004, 7, 166-72.	0.7	12
45	Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. <i>Gene</i> , 2017, 602, 16-23.	1.0	11
46	A novel murine PDGF-D splicing variant results in significant differences in peptide expression and function. <i>Biochemical and Biophysical Research Communications</i> , 2003, 308, 126-132.	1.0	9
47	Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma. <i>Virology Journal</i> , 2013, 10, 152.	1.4	9
48	Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells. <i>Virology Journal</i> , 2017, 14, 121.	1.4	8
49	Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110060.	0.5	7
50	Epstein - Barr virus latent membrane protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies. <i>Virology Journal</i> , 2011, 8, 461.	1.4	3
51	A New Piece to Help Solve the Interstitial Lung Disease Diagnostic Puzzle. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 158-160.	2.5	2
52	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. <i>Lung</i> , 2022, 200, 11-18.	1.4	2
53	Inhibition of HDAC8 Ameliorates Pulmonary Fibrosis. <i>FASEB Journal</i> , 2018, 32, lb400.	0.2	1
54	Hypercoagulability in ICU Patients With Coronavirus Disease 2019 With Respiratory Failure Results in Increased Prevalence of Venous Thromboembolic Disease. <i>Chest</i> , 2021, 159, 1208-1211.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Heparan sulfate 6-O-sulfation is dynamically regulated in idiopathic pulmonary fibrosis. FASEB Journal, 2012, 26, 1151.2.	0.2	0